Brief: Soleno Therapeutics Q3 EPS USD 0.47
04/11/2025 21:01
Nov 04 (Reuters) - Soleno Therapeutics Q3 operating income USD 22.105 million. Q3 net income USD 26.013 million Q3 basic EPS USD 0.49 Q3 operating expenses USD 43.913 million
Recent news on Soleno Therapeutics
See all newsNASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: EMA's CHMP Recommends Granting A Marketing Authorisation For Cenrifki (Tolebrutinib)